Physician profile
Rolando Borges
NPI 1457533234
$9,409.62
in general payments reported to CMS, 2019-2025
35 companies · $14.94 in 2025
The $14.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,986 · 2020: $2,443 · 2021: $2,467 · 2022: $350 · 2024: $149 · 2025: $14.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,308.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,307.40 | 2019-2021 | |
| Merz North America, INC. | $937.98 | 2019-2025 | |
| Allergan, INC. | $806.84 | 2019-2020 | |
| Lilly USA, LLC | $604.75 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $575.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.76 | 2019-2021 | |
| Amarin Pharma, INC. | $449.98 | 2019-2021 | |
| Abbvie INC. | $409.55 | 2021 | |
| Gilead Sciences, INC. | $333.53 | 2019-2021 | |
| Novo Nordisk INC | $273.23 | 2019-2021 | |
| Vifor Pharma, INC. | $249.98 | 2021-2022 | |
| Amgen INC. | $225.00 | 2020-2021 | |
| Pfizer INC. | $208.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $128.25 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $125.00 | 2020 | |
| Medtronic Vascular, INC. | $124.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $93.73 | 2019-2020 | |
| Astellas Pharma US INC | $90.75 | 2019-2021 | |
| Bausch Health US, LLC | $90.48 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $71.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $69.62 | 2021 | |
| Philips North America LLC | $60.14 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $50.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $49.04 | 2019 | |
| Sanofi Pasteur INC. | $40.47 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $35.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.84 | 2019 | |
| Irhythm Technologies, INC. | $17.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.07 | 2019 | |
| Seqirus USA INC | $16.79 | 2019 | |
| Abbott Laboratories | $16.49 | 2021 | |
| Strongbridge US INC. | $16.20 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Borges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.